替吉奥单药与联合奥沙利铂对胃癌化疗的临床研究

Clinical study on ticorgione single drug and ticorgione combined with oxaliplatin in chemotherapy for gastric cancer

目的探讨替吉奥单药与联合奥沙利铂对胃癌化疗的治疗效果。方法选择2015年6月至2016年6月我院接诊的D2根治术后组织学证实的100例Ⅱ期、ⅢA期进展期胃癌患者作为研究对象,以随机数表法分为观察组(55例)和对照组(45例),对照组使用替吉奥单药治疗,观察组给予替吉奥联合奥沙利铂治疗。比较两组治疗后疗效、无复发生存期、总生存期及不良反应发生情况。结果治疗后,两组患者总有效率分别为52.73%、28.89%,两组比较差异有统计学意义(P<0.05);两组患者2年无复发生存率比较差异无统计学意义(P>0.05);观察组患者1年无复发生存率、1年总生存率及2年总生存率均显著高于对照组(P<0.05);两组患者血小板计数下降发生情况比较差异无统计学意义(P>0.05);观察组患者白细胞计数下降、口腔黏膜炎、恶心呕吐、肝肾功能异常、腹泻及皮肤色素沉着发生率均显著低于对照组(P<0.05)。结论在胃癌患者中使用替吉奥联合奥沙利铂效果显著,可有效延长患者生存期,减少不良反应发生情况。

Objective To explore the therapeutic effect of ticorgione single drug and ticorgione combined with oxaliplatin on chemotherapy for gastric cancer. Methods Totally 100 patients with advanced gastric cancer of stage Ⅱ and ⅢA confirmed by histology after radical operation of D2 in our hospital from June 2015 to June 2016 were selected as study subjects. They were divided into observation group( n = 55) and control group( n = 45) by random number table method. Control group was treated with ticorgione alone,while observation group was treated with ticorgione combined with oxaliplatin. The curative effect, recurrence-free survival, total survival and adverse reactions were compared between the two groups. Results After treatment, the total effective rates of the two groups were 52. 73%and 28. 89%, respectively. There was significant difference between the two groups( P < 0. 05). There was no significant difference in 2-year recurrence-free survival rate between the two groups( P > 0. 05). The 1-year recurrence-free survival rate,1-year overall survival rate and 2-year overall survival rate in observation group were significantly higher than those in control group( P < 0. 05). There was no significant difference in the incidence of platelet count decrease between the two groups( P > 0. 05). The incidence of leukocyte count decrease,oral mucositis,nausea and vomiting, liver and kidney dysfunction,diarrhea and skin pigmentation in observation group was significantly lower than that in control group( P < 0. 05). Conclusion Ticorgione combined with oxaliplatin has a significant effect on patients with gastric cancer,which can effectively prolong the survival time of patients and reduce the incidence of adverse reactions.